Stock scanner
Ready-made scans
Fastest expected revenue growth under $2BCheap and profitableDividend payersNear their 52-week highBeaten down, finances improvingReporting this week
Filters
5,450 US-listed companies, filtered by valuation, profitability, growth, analysts' forecasts and momentum. Prices are from the October 9 close; company figures refresh weekly.
This data is 11 days old: the nightly update hasn't run since October 10.
The scanner turns your question into filters, and the results come straight from the data. The filters it chose show below, to check or change. You get 3 free questions a month.
5,450 companies match
| Company | Mkt cap | Price | P/E | EV/Sales | P/B | Yield | Net margin | ROIC | Rev growth | 1Y |
|---|---|---|---|---|---|---|---|---|---|---|
| NIUNiu Technologies | $155M | $1.97 | loss | 0.0 | 1.5 | 0.0% | −4.3% | −22.8% | 24.5% | −58.3% |
| QTRXQuanterix Corporation | $155M | $3.28 | loss | 0.9 | 0.6 | 0.0% | −80.3% | −46.9% | 23.4% | −41.8% |
| BETRBetter Home & Finance Holding Company | $155M | $9.86 | loss | n/a | 3.2 | 0.0% | −85.0% | n/a | 32.2% | −82.7% |
| HTLMHomesToLife Ltd | $154M | $1.72 | 1.8 | 0.3 | 6.5 | 3.8% | 4.3% | 57.3% | — | −48.1% |
| CCAQCollective Acquisition Corp. | $154M | $10.60 | 57.1 | — | 1.1 | 0.0% | — | −1.2% | — | +4.6% |
| TOROToro Corp. | $152M | $4.41 | 47.4 | 3.3 | 0.3 | 60.1% | 22.7% | −1.4% | −0.0% | +6.0% |
| IPHAInnate Pharma S.A. | $152M | $1.62 | loss | 137 | neg. eq. | 0.0% | −4554% | −381% | −77.9% | −20.2% |
| CDXSCodexis, Inc. | $152M | $1.41 | loss | 2.5 | 3.9 | 0.0% | −39.6% | −22.7% | 35.9% | −45.6% |
| FEAM5E Advanced Materials Inc. | $151M | $3.64 | loss | — | 2.4 | 0.0% | — | −63.9% | — | −35.7% |
| WHFWhiteHorse Finance, Inc. | $151M | $7.02 | 8.9 | 9.5 | 0.6 | 14.9% | 37.2% | 3.7% | 33.6% | +7.5% |
| FINWFinWise Bancorp | $151M | $10.99 | 10.7 | n/a | 0.7 | 0.0% | 6.8% | n/a | 88.8% | −39.8% |
| NAKANakamoto Inc. | $149M | $8.54 | loss | n/a | 0.7 | 0.0% | −1068% | n/a | 1658% | −75.5% |
| WWWW International, Inc. | $149M | $14.86 | loss | 0.7 | 0.5 | 0.0% | −14.8% | −3.0% | −8.7% | −42.9% |
| SIFSIFCO Industries, Inc. | $149M | $23.75 | 36.9 | 1.7 | 3.5 | 0.0% | 4.0% | 8.1% | 53.4% | +244% |
| EMLThe Eastern Company | $148M | $24.59 | 18.4 | 0.8 | 1.1 | 1.8% | 3.4% | 2.1% | −13.7% | +15.7% |
| STIMNeuronetics, Inc. | $148M | $2.13 | loss | 1.4 | 8.5 | 0.0% | −19.6% | −21.1% | 39.6% | −23.7% |
| DLTHDuluth Holdings Inc. | $148M | $3.90 | 24.4 | 0.5 | 0.8 | 0.0% | 1.1% | 4.0% | −8.6% | +20.0% |
| NERVMinerva Neurosciences, Inc. | $148M | $3.18 | loss | — | neg. eq. | 0.0% | — | −38.6% | — | +35.3% |
| VYGRVoyager Therapeutics, Inc. | $148M | $2.45 | loss | 4.2 | 1.0 | 0.0% | −313% | −62.4% | −19.1% | −51.0% |
| SKYXSKYX Platforms Corp. | $148M | $1.10 | loss | 1.6 | 7.9 | 0.0% | −34.3% | −54.5% | 8.1% | −2.7% |
| NCOSouthern Cross Acquisition I Corp. | $147M | $9.96 | — | — | — | 0.0% | — | — | — | +1.3% |
| VRAVera Bradley, Inc. | $146M | $5.14 | loss | 0.7 | 1.1 | 0.0% | −3.7% | −4.1% | −6.3% | +158% |
| EGANeGain Corporation | $146M | $5.32 | 16.5 | 0.8 | 1.7 | 0.0% | 9.7% | 7.3% | 3.1% | −58.4% |
| OCLTOceanLight Acquisition Corp. | $146M | $9.90 | — | — | — | — | — | — | — | 0.0% |
| BREZBreeze Acquisition Corp. II | $145M | $10.05 | loss | 45.7 | — | 0.0% | −163% | −220% | — | +1.3% |
| OZBelpointe PREP, LLC | $145M | $37.07 | loss | 27.1 | 0.6 | 0.0% | −290% | −2.9% | 164% | −42.1% |
| MOLNMolecular Partners AG | $144M | $3.85 | loss | — | 2.0 | 0.0% | — | −76.9% | −100% | +1.3% |
| RNAAtrium Therapeutics, Inc. | $144M | $8.40 | loss | 3.1 | 0.7 | 0.0% | −397% | −38.4% | — | −43.1% |
| COOKTraeger, Inc. | $144M | $51.60 | loss | 1.0 | 0.8 | 0.0% | −23.2% | −0.8% | −16.3% | +4.2% |
| CTWCTW Cayman Class A Ordinary Shares | $144M | $2.30 | 36.0 | 1.5 | 5.0 | 0.0% | 4.2% | −2.0% | 32.1% | +2.2% |
| LSBKLake Shore Bancorp, Inc. | $144M | $18.25 | 16.3 | n/a | 0.9 | 2.0% | 20.7% | n/a | 5.6% | +41.7% |
| NEOVNeoVolta Inc | $143M | $2.61 | loss | 9.2 | 3.2 | 0.0% | −161% | −40.3% | 58.2% | −51.9% |
| NLOPNet Lease Office Properties | $143M | $9.67 | loss | 1.8 | 0.9 | 199% | −58.7% | 31.4% | −34.2% | −66.2% |
| IMRXImmuneering Corporation | $143M | $3.94 | loss | — | 1.3 | 0.0% | — | −32.7% | — | −35.7% |
| BCBPBCB Bancorp, Inc. | $143M | $8.23 | loss | n/a | 0.5 | 5.8% | −12.0% | n/a | −22.9% | +3.7% |
| TRAKReposiTrak, Inc. | $143M | $7.86 | 19.3 | 5.0 | 2.7 | 1.0% | 32.5% | 11.6% | 3.0% | −45.0% |
| TRNZTrinity Capital, Inc. 7.875 % Notes 2024-30.03.2029 | $142M | $25.05 | — | — | — | 3.9% | — | — | — | −0.5% |
| VNCEVince Holding Corp. | $142M | $11.09 | 18.8 | 0.8 | 2.4 | 0.0% | 2.4% | 4.6% | 8.0% | +288% |
| NGENNervGen Pharma Corp. Common stock | $142M | $1.73 | loss | — | 96.6 | 0.0% | — | −720% | — | −59.5% |
| NANano Labs Ltd | $142M | $2.11 | loss | 0.0 | 0.8 | 0.0% | 500% | 11575% | 111830% | −59.5% |
| SLNHSoluna Holdings, Inc. | $142M | $0.90 | loss | 1.6 | 0.8 | 0.0% | −182% | −20.1% | 50.9% | −62.7% |
| FACFactorial Energy Inc. | $142M | $5.14 | loss | — | 2.1 | 0.0% | — | −14.6% | — | −49.0% |
| CRDLCardiol Therapeutics Inc. | $142M | $1.23 | loss | — | 8.4 | 0.0% | — | −149% | — | +18.3% |
| DOUGDouglas Elliman Inc. | $141M | $1.55 | 6.0 | 0.1 | 0.8 | 0.0% | 2.5% | −13.4% | −2.7% | −40.4% |
| CANCanaan Inc. | $141M | $0.30 | loss | 0.3 | 0.7 | 0.0% | −67.8% | −42.3% | 27.9% | −72.5% |
| RZAIRoze AI Inc. | $141M | $10.15 | — | — | — | — | — | — | — | −62.4% |
| CEPLCapstone Energy+, Inc. | $140M | $4.36 | loss | 1.4 | 5.0 | 0.0% | 3.5% | 6.7% | — | −63.5% |
| ACOGAlpha Cognition Inc | $140M | $9.04 | loss | 6.5 | 3.7 | 0.0% | −154% | −50.0% | 233% | +28.8% |
| MRDNMeridian Holdings Inc. | $140M | $11.09 | loss | 0.7 | 2.8 | 0.0% | −41.4% | 6.2% | 14.1% | −4.0% |
| DMRCDigimarc Corp. | $140M | $6.25 | loss | 4.4 | 4.7 | 0.0% | −99.8% | −91.1% | −11.2% | −24.1% |
Showing 3,851–3,900 of 5,450
A blank means a figure isn't reported or doesn't mean anything for that company: there's no P/E for a company losing money, no EV/Sales for a bank, no P/B when a company owes more than it owns. A filter on that figure leaves the company out. Growth compares the last twelve months with the twelve before. Figures describe the companies; they aren't advice to buy or sell anything.